Athenex, Inc. (ATNX) News
Filter ATNX News Items
ATNX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ATNX News Highlights
- ATNX's 30 day story count now stands at 5.
- Over the past 1 day, the trend for ATNX's stories per day has been choppy and unclear. It has oscillated between 2 and 3.
- APD, CELL and KKR are the most mentioned tickers in articles about ATNX.
Latest ATNX News From Around the Web
Below are the latest news stories about ATHENEX INC that investors may wish to consider to help them evaluate ATNX as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on Monday morning! |
SOFI Stock Sinks 10% on Analyst DowngradeSoFi Technologies (SOFI) stock is on the move Monday after the finance company's stock was hit with a downgrade Wedbush. |
Why Is Athenex (ATNX) Stock Down 54% Today?Athenex (ATNX) stock is falling on Monday after the company announced an agreement with lenders to pursue an expedited sales process. |
Why Is Greenbrook TMS (GBNH) Stock Down 9% Today?Greenbrook TMS (GBNH) stock is on the move Monday as the therapy center prepares to release its latest earnings report later today. |
Athenex Voluntarily Filed For Chapter 11 Proceedings, Shares PlungeOn Sunday, Athenex Inc (NASDAQ: ATNX) and certain of its subsidiaries voluntarily filed for Chapter 11 proceedings. Athenex agreed with its lenders to move forward with an expedited sale process of its assets, the company said in a statement. The company has listed estimated assets and liabilities of around $100 million-$500 million, Reuters reported citing a filing with the U.S. Bankruptcy Court for the Southern District of Texas. The company said the assets would be sold across its primary bus |
Credit Crunch Fuels 48-Hour Bankruptcy Rush With Seven Filings(Bloomberg) -- At least seven large companies filed for Chapter 11 bankruptcy protection in less than 48 hours, a breakneck pace of restructurings that included once-hot digital-broadcaster Vice Media LLC and KKR & Co.-backed Envision Healthcare Corp. Most Read from BloombergTurkey Latest: Erdogan Says Unclear If Vote Will Go to RunoffTurkey Set for Runoff as Erdogan Falls Just Short of VictoryS&P ETF Barely Budges on Yellen’s Late-Day Notice: Markets WrapMicrosoft’s $69 Billion Activision Deal |
Drugmaker Athenex voluntarily files for U.S. Chapter 11 proceedingsThe Buffalo, New York-based company has listed estimated assets and liabilities in the range of $100 million-$500 million, according to a filing with the U.S. Bankruptcy Court for the Southern District of Texas. The assets to be sold would be across its primary businesses of Athenex Pharmaceutical Division (APD), Orascovery, and Cell Therapy, the company said, adding that it expects the expedited process to be completed by July 1, 2023. |
UPDATE 1-Drugmaker Athenex voluntarily files for U.S. Chapter 11 proceedingsDrugmaker Athenex Inc and certain of its subsidiaries voluntarily filed for Chapter 11 proceedings, the company said on Sunday. The Buffalo, New York-based company has listed estimated assets and liabilities in the range of $100 million-$500 million, according to a filing with the U.S. Bankruptcy Court for the Southern District of Texas. The assets to be sold would be across its primary businesses of Athenex Pharmaceutical Division (APD), Orascovery, and Cell Therapy, the company said, adding that it expects the expedited process to be completed by July 1, 2023. |
Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales ProcessTo Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings Company Has Sufficient Resources to Support Athenex Pharma Solutions Operations and Fulfill APD Customer Orders During Process BUFFALO, N.Y., May 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX) (“Athenex” or the “Company”), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that, follo |
Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCOQuantum Leap Healthcare Collaborative (Quantum Leap) and Athenex, Inc. (Nasdaq: ATNX) will present the findings of the I-SPY 2 TRIAL evaluation of Athenex's oral paclitaxel plus encequidar in combination with GSK's dostarlimab in the neoadjuvant setting at this year's American Society of Clinical Oncology (ASCO) conference. |